Back to today’s briefing

Story perspectives

SSRIs Show Promise in Shrinking Tumors, Boosting Remission

5/22/2025

50 7

Summary

Story summary

UCLA research reveals a groundbreaking discovery: selective serotonin reuptake inhibitors (SSRIs), typically used for depression, may shrink tumors by boosting T cell activity. Remarkably, when paired with immunotherapies, some patients achieved complete remission. This promising finding paves the way for future studies on cancer patients already using these antidepressants.

1 of 1

Story summary

UCLA research reveals a groundbreaking discovery: selective serotonin reuptake inhibitors (SSRIs), typically used for depression, may shrink tumors by boosting T cell activity. Remarkably, when paired with immunotherapies, some patients achieved complete remission. This promising finding paves the way for future studies on cancer patients already using these antidepressants.